SPARINGVISION
π«π·France
- Country
- π«π·France
- Ownership
- -
- Established
- 2016-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://sparingvision.com
Clinical Trials
5
Active:1
Completed:0
Trial Phases
2 Phases
Phase 1:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)β’ Click on a phase to view related trials
Phase 1
3 (75.0%)Not Applicable
1 (25.0%)Promising ROd-cone DYstrophy Gene therapY
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- SparingVision
- Target Recruit Count
- 33
- Registration Number
- NCT05748873
- Locations
- πΊπΈ
Bascom Palmer Eye Institute/University of Miami, Miami, Florida, United States
πΊπΈCasey Eye Institute, Portland, Oregon, United States
πΊπΈUPMC Eye Center, Pittsburgh, Pennsylvania, United States
Prospective Natural History Study of Retinitis Pigmentosa
Not Applicable
Active, not recruiting
- Conditions
- Retinitis Pigmentosa
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- SparingVision
- Target Recruit Count
- 82
- Registration Number
- NCT04285398
- Locations
- πΊπΈ
UPMC Eye Center, Pittsburgh, Pennsylvania, United States
π«π·CHNO XV-XX Paris - CIC 1423, Paris, France
Retrospective Natural History Study of Retinitis Pigmentosa
- Conditions
- Retinitis Pigmentosa (RP)
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- SparingVision
- Target Recruit Count
- 113
- Registration Number
- NCT03975543
- Locations
- π«π·
CHNO XV-XX Paris - CIC 1423, Paris, France
News
Beacon Therapeutics Appoints Gene Therapy Veteran Dr. Daniel Chung as Chief Medical Officer
Beacon Therapeutics has appointed Dr. Daniel Chung as Chief Medical Officer, bringing over three decades of experience in clinical ophthalmology and gene therapy development.